Department of Brain Health News
The department of brain health is dedicated to advancing research, education, and clinical care to benefit brain health and the care and treatment of people with brain disorders across the lifespan. The faculty specializes in several areas that range from basic to clinical research in neurodegenerative disease and stroke.
Current Brain Health News
The top news stories starring university students and staff.
Data provided by UNLV researchers helped secure FDA approval for a new blood test to detect Alzheimer’s disease.
The top headlines featuring UNLV’s staff and students.
Report led by noted Alzheimer's researcher Dr. Jeffrey Cummings assesses status, trends associated with 182 active clinical trials worldwide.
UNLV research team says high blood sugar levels appear to weaken function in key part of brain, mimicking Alzheimer’s.
The 'Brain Health Frontiers: Tackling Alzheimer's Together' panel discussion highlighted the revolutionary research the Department of Brain Health is conducting to fight Alzheimer’s disease.
Brain Health In The News
Over the past few years, scientists have learned that Ozempic and related drugs developed to treat Type 2 diabetes can improve the health of the liver, kidney and heart. Is it such a stretch to think they could also treat neurological disorders? Perhaps — at least when it comes to Alzheimer’s disease.
Alzheimer's patients treated with the GLP-1 receptor agonist semaglutide (Rybelsus) in two phase III trials showed no significant improvement in cognitive or functional decline over 2 years compared with placebo, according to new data presented at the Clinical Trials on Alzheimer's Disease (CTAD) annual meeting.
Detailed results from the phase 3 EVOKE and EVOKE+ trials of the oral GLP-1 receptor agonist semaglutide (Ozempic, Novo Nordisk) in early Alzheimer’s disease (AD) have been presented. The initial negative topline results announced last week by the company were met with disappointment in the AD research community, but the newly presented biomarker data offer some grounds for optimism and may point to a potential path forward.
Details from two large trials of Novo Nordisk's NOVOb.CO GLP-1 drug semaglutide showed it provided no cognitive benefit for people with early Alzheimer's disease, researchers said at a medical meeting on Wednesday, dashing remaining hopes that the widely used medication could help such patients.
When Herriot Tabuteau launched his drug development company, Axsome Therapeutics, in 2012, he decided to do things differently by focusing on treatments for brain disorders that are particularly challenging to develop. Now, he’s sitting on a $6 billion empire, according to Forbes.
Detect Alzheimer's disease early with a groundbreaking blood test that could change the game for millions of people worldwide! This revolutionary diagnostic tool can identify the disease years before symptoms appear, giving patients and their families a head start on treatment and care. The FDA just cleared the first blood test for identifying patients with amyloid pathology associated with Alzheimer’s disease — and part of the research behind its approval was conducted by leading experts at the UNLV Department of Brain Health, with chair and renowned brain health researcher, Jefferson Kinney, PhD, our guest for today’s Show. In this video, we'll dive into the science behind this innovative test, how it works, and what it means for the future of Alzheimer's research and treatment. If you or a loved one is at risk for Alzheimer's, you won't want to miss this!
